SEC Comment Letter 0000000000-24-014015 to Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences, Inc.
Date: Dec. 19, 2024 · CIK: 0000890821 · Accession: 0000000000-24-014015

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

December 19, 2024

Author

Joseph Tucker

Form

UPLOAD

Company

Enveric Biosciences, Inc.

Letter

December 19, 2024 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N., Suite 200 Naples, FL 34103 Re:Enveric Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed November 27, 2024 Dear Joseph Tucker: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Bradley Wyatt

Show Raw Text

December 19, 2024
Joseph Tucker
Chief Executive Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N., Suite 200
Naples, FL 34103
Re:Enveric Biosciences, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed November 27, 2024
Dear Joseph Tucker:
            We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Bradley Wyatt

SecProbe.io